

IN THE CLAIMS:

The status of each claim that has been introduced in the above-referenced application is identified in the ensuing listing of the claims. This listing of the claims replaces all previously submitted claims listings.

1. (Currently amended) A composition for treating a cardiovascular disorder, comprisingconsisting essentially of:
an inflammation-reducing component for decreasing an amount of inflammation in blood vessels of a subject, comprising transfer factor specific for at least one pathogen that directly causes a cardiovascular disorder treated with the composition or for at least one antigen of at least one pathogen that directly causes the treated cardiovascular disorder of herpes simplex virus type I, herpes simplex virus type II, cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori; and
at least one low density lipoprotein (LDL) receptor-binding component;
at least one blood cholesterol reduction component;
at least one blood flow-enhancing component; and
at least one antioxidant.

2. (Canceled)

3. (Canceled)

4. (Previously presented) The composition of claim 1, wherein said transfer factor comprises nonmammalian transfer factor.

5. (Original) The composition of claim 4, wherein said nonmammalian transfer factor comprises avian transfer factor.

6. (Original) The composition of claim 5, wherein said avian transfer factor comprises at least a part of an egg extract.
7. (Previously presented) The composition of claim 1, wherein said transfer factor comprises mammalian transfer factor.
8. (Original) The composition of claim 7, wherein said mammalian transfer factor comprises at least a part of a colostrum extract.
9. (Canceled)
10. (Canceled)
11. (Currently amended) The composition of claim 10, wherein said at least one LDL receptor-binding component comprises lysine or a lysine salt.
12. (Currently Amended) The composition of claim 1, wherein said at least one blood flow-enhancing component comprises at least one of an arginine-containing compound and nicotinamide.
13. (Canceled)
14. (Currently amended) The composition of claim 13, wherein said at least one antioxidant comprises at least one hydrophobic antioxidant.
15. (Original) The composition of claim 14, wherein said at least one hydrophobic antioxidant comprises at least one of beta-carotene, vitamin A, and vitamin E.

16. (Original) The composition of claim 13, wherein said at least one antioxidant comprises Coenzyme Q₁₀.

17. (Canceled)

18. (Original) The composition of claim 1, further comprising a fat oxidation prevention element.

19-49 (Canceled)

50. (Currently amended) A composition for treating a cardiovascular disorder, comprising consisting essentially of:
a pathogen-reducing component for decreasing a number of pathogens in blood vessels of a subject, comprising at least one type of transfer factor specific for at least one of herpes simplex virus type I, herpes simplex virus type II, cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori pathogen that directly causes a cardiovascular disorder treated with the composition or for at least one antigen of at least one pathogen that directly causes the treated cardiovascular disorder; and
at least one blood flow-enhancing component.

51. (Canceled)

52. (Canceled)

53. (Previously presented) The composition of claim 50, wherein said transfer factor comprises nonmammalian transfer factor.

54. (Original) The composition of claim 53, wherein said nonmammalian transfer factor comprises avian transfer factor.

55. (Original) The composition of claim 54, wherein said avian transfer factor comprises at least a part of an egg extract.

56. (Previously presented) The composition of claim 50, wherein said transfer factor comprises mammalian transfer factor.

57. (Original) The composition of claim 56, wherein said mammalian transfer factor comprises at least a part of a colostrum extract.

58. (Canceled)

59. (Original) The composition of claim 50, further comprising: an LDL receptor-binding component.

60. (Original) The composition of claim 59, wherein said LDL receptor-binding component comprises lysine or a lysine salt.

61. (Currently Amended) The composition of claim 50, wherein said at least one blood flow-enhancing component comprises at least one of an arginine-containing compound and nicotinamide.

62. (Original) The composition of claim 50, further comprising: at least one antioxidant.

63. (Original) The composition of claim 62, wherein said at least one antioxidant comprises at least one hydrophobic antioxidant.

64. (Previously presented) The composition of claim 63, wherein said at least one hydrophobic antioxidant comprises at least one of beta-carotene, vitamin A, and vitamin E.

65. (Original) The composition of claim 62, wherein said at least one antioxidant comprises Coenzyme Q₁₀.

66. (Original) The composition of claim 50, further comprising a cholesterol-reducing element.

67. (Original) The composition of claim 50, further comprising a fat oxidation prevention element.

68. (Currently Amended) A composition, comprisingconsisting essentially of: a preparation including avian transfer factor specific for at least one of HSV-I, HSV-II, *Chlamydia pneumoniae*, cytomegalovirus, and *Helicobacter pylori*; Vitamin C; niacinamide; a form of an arginine-containing compound; and a form of lysine-containing compound.

69. (Currently amended) The composition of claim 68, wherein: the form of arginine-containing compound comprises magnesium arginate; and the the form of lysine-containing compound comprises magnesium lysinate.

70. (Previously presented) The composition of claim 68, comprising the preparation including transfer factor and the Vitamin C in substantially equal amounts.

71. (Previously presented) The composition of claim 68, wherein the transfer factor is specific for at least one pathogen that directly causes a cardiovascular disorder or at least one antigen of at least one pathogen that directly causes the cardiovascular disorder.

72. (Currently amended) A composition, comprising:
substantially a first amount of a preparation including transfer factor; and
substantially the first amount of Vitamin C.

73. (Previously presented) The composition of claim 72, wherein the transfer factor is specific for at least one pathogen that directly causes a cardiovascular disorder or at least one antigen of at least one pathogen that directly causes the cardiovascular disorder.

74. (Previously presented) The composition of claim 73, further comprising at least one LDL receptor-binding element, at least one blood flow-enhancing element, and at least one blood cholesterol reducer.

75. (Currently Amended) The composition of claim 74, wherein the at least one LDL receptor-binding element comprises a lysine-containing compound and the at least one blood flow-enhancing element comprises an arginine-containing compound.

76. (Previously presented) The composition of claim 75, wherein the at least one blood cholesterol reducer comprises niacinamide.

77. (Currently amended) The composition of claim 75, wherein the lysine-containing compound comprises magnesium lysinate and the arginine-containing compound comprises magnesium arginate.

78. (Previously presented) The composition of claim 77, wherein the at least one blood cholesterol reducer comprises niacinamide.